Cargando cotizaciones...
Previsión
| Comprar |
2 |
| Mantener |
0 |
| Vender |
0 |
Noticias Ir al feed de noticias
Phio Pharmaceuticals secures patent grants in US, Canada and Japan
Phio Pharmaceuticals reports three patent allowances and one grant decision to protect its INTASYL active agents in the US, Canada and Japan. The portfolio now comprises 54 granted patents covering chemistry, gene targets, immuno-oncology agents and indications. The company views the expanded protection as supporting strategic partnerships and commercialization, but with a market capitalization of USD 11.97 million and a negative free cash flow of USD 10.72 million it remains in the capital-intensive clinical development phase. The stock trades below InvestingPro’s fair-value estimate. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | jun 2026 | |
|---|---|---|
| Ingresos | 0,00 | - |
| Beneficio bruto | −876,21 | 99,90% |
| Beneficio neto | −3,63M | 97,30% |
| EBITDA | −3,74M | 103,50% |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 11,98M€ |
Número de acciones | 11,62M |
Máximo/mínimo de 52 semanas | 3,60€ - 0,70€ |
| Dividendos | No |
Beta | 0,79 |
Ratio P/E | −0,90 |
Ratio PEG | −0,01 |
Ratio P/B | 1,11 |
Ratio P/S | 0,00 |
Perfil de la empresa
| Nombre | Phio Pharmaceuticals Corp |
| CEO | Robert L. Bitterman |
| Empleados | 6 |
Descubrir activos
Los accionistas de Phio Pharmaceuticals Corp también invierten en los siguientes activos
